Addex Therapeutics Ltd (ADXN)

Addex Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.38	1.65	1.44	3.15	3.88	2.83
Revenue Growth (YoY)	-18.97%	13.99%	-54.18%	-18.71%	36.89%	-57.72%
Gross Profit	1.38	1.65	1.44	3.15	3.88	2.83
Selling, General & Admin	4.55	4.97	7.3	5.82	5.75	4.98
Research & Development	5.5	6.96	14.67	12.84	10.37	12.45
Operating Expenses	10.05	11.93	21.97	18.66	16.12	17.44
Operating Income	-8.67	-10.28	-20.52	-15.51	-12.24	-14.6
Interest Expense / Income	0.31	0.34	0.31	0.06	0.65	0.21
Other Expense / Income	2.26	-0.06	-0.03	-0.22	-0.04	-0.04
Pretax Income	-11.24	-10.56	-20.8	-15.35	-12.86	-14.78
Net Income	-11.24	-10.56	-20.8	-15.35	-12.86	-14.78
Shares Outstanding (Basic)	75	75	38	27	27	26
Shares Change	25.49%	97.79%	42.03%	-0.07%	0.73%	-
EPS (Basic)	-0.13	-0.14	-0.46	-0.45	-0.48	-0.56
EPS (Diluted)	-0.13	-0.14	-0.46	-0.45	-0.48	-0.56
Free Cash Flow	-7.83	-8	-16.44	-14.74	-12.24	-9.51
Free Cash Flow Per Share	-12.54	-12.81	-52.08	-66.31	-55.03	-43.08
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-628.28%	-624.22%	-1420.12%	-491.74%	-315.62%	-515.38%
Profit Margin	-814.26%	-640.91%	-1439.78%	-486.85%	-331.48%	-521.61%
Free Cash Flow Margin	-567.54%	-485.67%	-1137.59%	-467.34%	-315.52%	-335.63%
EBITDA	-10.63	-9.91	-20.17	-14.94	-11.83	-14.23
EBITDA Margin	-770.16%	-601.76%	-1395.74%	-473.83%	-304.94%	-502.30%
Depreciation & Amortization	0.3	0.31	0.32	0.35	0.38	0.33
EBIT	-10.93	-10.22	-20.49	-15.29	-12.21	-14.57
EBIT Margin	-791.94%	-620.33%	-1418.10%	-484.85%	-314.71%	-514.08%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).